Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

This study found that Bacillus/Trapa japonica fruit ferment filtrate extracts enhanced human hair follicle dermal papilla cell proliferation through the Akt/ERK/GSK-3β signaling pathway, suggesting potential benefits for alopecia treatment.

This review discusses the role of androgen metabolism in hair follicles and its potential impact on future treatments for androgenetic alopecia, but reports no clinical results.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.

This study found that the pH dependency of rat steroid 5α-reductase type II isozyme significantly affects its kinetic properties, including Vmax and Km, suggesting past discrepancies in literature may arise from these pH variances during assays.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.

This study found that among 17 beta-(N-ureylene-N,N'-disubstituted)-4-azasteroids, those with an N'-phenyl moiety were the most effective inhibitors of human type I 5 alpha-reductase.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This review suggests that most mutations in the SRD5A2 gene show no clear genotype-phenotype correlation in 5-α-Reductase deficiency, although mutation location affects severity.

In this study of male patients with 46,XY 5α-reductase type 2 deficiency, DHT therapy was effective in achieving penile enlargement during infancy, while testosterone replacement therapy proved more beneficial during puberty, possibly due to increased conversion to DHT.

This study identified that methylation of the 5-AR2 gene promoter is linked to reduced expression of 5-AR2 protein, which may explain why some BPH patients are resistant to finasteride treatment.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This study found that variations in sleep patterns, free testosterone, and 5-alpha-reductase type 1 activity are associated with changes in sebum excretion in women, which may contribute to variability in acne studies.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

This study found that combining shikimic acid with Prunus mume fruit extract significantly reduces type I 5α-reductase levels in testosterone-stressed skin sebocytes, surpassing the effects of shikimic acid or standard acne treatments alone, and shows promise for stable, non-irritating acne remedies in cosmetic formulations.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.